Autoliv hikes sales forecast as tariff costs shift to automakers
The world's largest maker of airbags and seat belts is mostly affected by tariffs between the United States and Mexico and Canada. U.S. President Donald Trump has threatened to raise tariffs on imports from both of these countries to 30% and 35%, respectively, from August.
U.S. tariffs on foreign auto imports are expected to raise car prices by thousands of dollars, reducing demand and hurting job growth, rattling an industry already struggling with a difficult transition to electric vehicles.
"We recovered around 80% of tariff costs in the second quarter, and we expect to recover most of what remains later in the year," CEO Mikael Bratt said, adding that the company remained confident it could continue to successfully receive compensation from its customers for tariffs.
"There's no logic whatsoever why the suppliers or the value chain should absorb this," he added.
Autoliv - customers of which include most of the largest automakers such as Volkswagen, Stellantis and Toyota - said it now sees organic sales growth this year of around 3%. Its previous forecast, last reiterated in April, was for 2%.
Analysts at Jefferies said in a note to clients that the results again demonstrated Autoliv's resilience in a quarter with significant tariff volatility.
Adjusted operating profit grew in line with expectations to $251 million from a year-earlier $221 million, with organic sales growth of 3%.
Its adjusted operating margin was 9.1%, a near industry-leading margin, according to analysts at Citi.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Auto Express
24 minutes ago
- Auto Express
This car giant is £260m down thanks to Trump and his tariffs
President Trump's tariffs are starting to bite across the car industry, if the latest news from the owner of Citroen, Peugeot, Vauxhall, Fiat and Jeep is anything to go by. The multi-brand Stellantis group says that it's in a 300m Euro (£260m) hole as a result of extra costs associated with importing cars to the US market. Advertisement - Article continues below The fall in revenue resulting from the tariffs contributed to a 2.3 billion Euro loss in the first half of 2025. But given that the measures were only imposed part of the way through that reporting period, worse could be still to come. "We'll see significantly more in the second half unless things change," said Doug Ostermann, Stellantis Chief Financial Officer. 'Given the current outlook, I would expect to see that figure probably double in the second half, or more.' Stellantis revealed that shipments to North America declined by 25 per cent in the three months to June compared with the same period last year. The likes of Peugeot, Citroen and Vauxhall don't have a presence in the US market, but Stellantis also owns Jeep, Chrysler, Dodge and Ram, as well as Alfa Romeo and Maserati, which do. US customers might end up paying more for cars but you don't have to. Check out the latest deals on the Auto Express Find a Car service. The giant Stellantis group does manufacture cars in the US but has a total of 52 plants in other countries around the world - including in Europe, Canada and South America - that import vehicles to the US market. The global nature of the car industry means that there will be other brands in a similar boat, both those importing completed vehicles and those sending components to feed US factories - although Trump did take measures to lower tariffs on these components in April. The UK arrived at a trade deal with the US government in May that lowered the 25 per cent tariffs on complete cars built here to 10 per cent, but this is still significantly higher than the previous tariff of 2.5 per cent. There could be further problems for Stellantis if President Trump follows through on his threat to impose 50 per cent tariffs on Brazil. The group has a major manufacturing operation there producing Fiat and Jeep cars. Come and join our WhatsApp channel for the latest car news and reviews...
Daily Mail
25 minutes ago
- Daily Mail
AstraZeneca to invest $50B in US as tariff threat looms
AstraZeneca plans to plough billions of pounds into US manufacturing as the drugs giant faces the threat of looming tariffs. There are also reports the FTSE 100 pharmaceuticals giant plans to abandon London as its home. AstraZeneca on Tuesday said it would invest $50 billion (£37.1 billion) in the US by 2030, creating 'tens of thousands' of highly skilled 'direct and indirect' jobs, while 'powering growth and delivering next generation medicines'. Boss Pascal Soriot told investors in April the drugmaker is 'firmly committed to investing and growing in the US' as the White House continues to threaten the sector with looming tariffs on US imports. President Donald Trump last week outlined a plan to introduce levies that would steadily climb higher over time with the potential to hit 200 per cent after a 'year, year and a half'. Trump said: 'We're going to start off with a low tariff and then give the pharmaceutical companies a year or so to build and then we're going to make it a very high tariff. 'There's two ways you do it. You make money and/or you have them move here so they don't have to pay the tariff.' Howard Lutnick, US Secretary of Commerce, said on Thursday: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness.' It also comes amid reports Soriot is weighing moving AstraZeneca's headquarters away from the UK as well as its main stock market listing. Soriot, 66, has lambasted the UK and the rest of Europe for falling behind other countries such as the US and China in developing medicines. AstraZeneca is planning its 'largest single manufacturing investment in the world' in the state of Virginia, with the site earmarked to produce drug substances for its weight management and metabolic portfolio. 'The facility will leverage AI, automation, and data analytics to optimise production,' AstraZeneca said. The rest of the investment will boost AstraZeneca's existing R&D and manufacturing facilities among other plans. AstraZeneca said the investments will help deliver its target of reaching $80 billion in total revenue by 2030, of which it expects 50 per cent would be generated in the US. Soriot said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.' UK government 'will be kicking itself' AstraZeneca's decision will come as a blow to the Labour government as it struggles to encourage firm's to invest in the UK. Russ Mould, investment director at AJ Bell, said the government 'will be kicking itself', with the country set to miss out on associated economic benefits of the investment. He added: 'That money, if invested in the UK, would have created a large number of jobs and help shine a light on the country for scientific excellence. 'AstraZeneca pulling out of a £450 million vaccine plant expansion in Liverpool earlier this year was the big clue that it was losing patience with the UK government. 'At the time, it hinted that without a certain level of support, it wasn't financially viable to invest that money. The previous government had pledged £90 million in grants and other aid, but the support was cut when Labour came to power. 'The more business it does in...[the US], the greater the likelihood that investors might push for AstraZeneca to switch its main stock listing to the US. That would be bad for the UK stock market as it is one of the biggest names in the FTSE 100.'
Reuters
an hour ago
- Reuters
Coca-Cola beats on zero-calorie sodas, higher prices; to launch cane sugar-based drink
July 22 (Reuters) - Coca-Cola (KO.N), opens new tab beat estimates for quarterly revenue and profit on Tuesday, benefiting from resilient demand for zero-calorie drinks as well as higher pricing, and laid out plans to launch a new product made with cane sugar in the U.S. this year. Food companies are increasingly looking to include healthier substitutes as they respond to Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again campaign. Last week, President Donald Trump said Coca-Cola had agreed to use real cane sugar in the U.S. While there are some slight differences between cane sugar and corn syrup as sweeteners, experts have said that too much of either is not good for consumers. Coca-Cola already sells Coke made from cane sugar in other markets, including Mexico, and some U.S. grocery stores carry glass bottles with cane sugar labeled "Mexican" Coke. The switch to cane sugar will also drive up costs for the company, industry analysts have said. Changes in the formulation of the rest of the Coke sold in the U.S., and other beverages and candies, would involve significant adjustments to supply chains. Rival PepsiCo (PEP.O), opens new tab, which topped quarterly earnings estimates last week, also said it would use natural ingredients in its products if consumers want it. Coca-Cola reiterated that the hit to costs due to "global trade dynamics" remained manageable. The company has said it would look at affordable packaging options such as plastic bottles when Trump imposed a 25% duty on aluminum imports. As of June, tariffs on aluminum imports have doubled to 50%. Coca-Cola's comparable revenue rose 2.5% to $12.62 billion in the second quarter, beating estimates of $12.54 billion, according to data compiled by LSEG. Annual comparable earnings per share is expected to be near the top end of its target of a 2% to 3% rise, helped by a weaker dollar. Volumes fell in North America "due to the continued uncertainty and pressure on some socioeconomic segments of consumers," CEO James Quincey said on a post-earnings call. Demand for pricey sodas has remained choppy in recent quarters, especially in developed countries as consumers, especially in lower-income segments, turned more price-sensitive. Coca-Cola's volumes slipped 1% in the three months ended June 27 after rising 2% each in the previous two quarters, largely due to declines in key markets such as Mexico and India, as well as for its Coca-Cola brand in the U.S. Quincey added that a boycott-related hit to demand in the U.S. and Mexico was now largely resolved. Volumes had fallen in the first half of the year in North America due to Hispanic consumers in the U.S. and Mexico boycotting the company's legacy brands after a viral video of Coca-Cola laying off Latino staff and reporting them to Immigration and Customs Enforcement. Prices rose 6% overall in the second quarter, led by increases in some inflationary markets. Coca-Cola's shares fell 1% in early trading. They have risen 12.5% this year, as of Monday's close. Coca-Cola Zero Sugar volume jumped 14%, driven by growth across all geographies, and was a bright spot in the quarter. Excluding items, the company earned 87 cents per share, beating estimates of 83 cents.
